Progyluton Tablet Estradiol valerate 2mg Norgestrel Best Oral Uses

---

---

Progyluton Tablet (Estradiol Valerate–Norgestrel) Oral Uses in Urdu

---

Progyluton Tablet (Estradiol Valerate–Norgestrel) Oral Uses in Urdu

Composition qualitative and quantitative 

Progyluton Tablet Each white sugar-coated tablet contains estradiol valerate 2.0mg

Each light brown sugar-coated tablet contains estradiol valerate 2.0mg and norgestrel 0.5mg

Progyluton Tablet (Estradiol Valerate–Norgestrel) Oral Uses in Urdu

• Indication Of Progyluton Tablet Oral Uses
• progyluton tablet for polymenorrhea means menses in more than one time in the month 
• primary and secondary amenorrhea means the absence of menses in puberty or menses is stop more than 6month
• irregular menses 
• it provides hormone which produces an egg from ovary  than ovulation occurs
• menopause  menses is skipped in age 4o to 50 year more than in over 50 years of age
• abnormal uterine bleeding means Menorrhagia 
• female infertility if a female try to conceive the result some make positive through this medicine
• Hormone replacement therapy (HRT) for the treatment of signs and symptoms of estrogen deficiency due to natural menopause or Hypogonadism, castration or primary ovarian failure in women with an intact uterus.
• prevention of postmenopausal osteoporosis.
• Control of irregular menstrual cycles.
• Treatment of primary or Secondary amenorrhea.
• 

 

---

---

Progyluton Oral Uses Side effects

---

---

1. Nausea
2. vomiting
3. headache
4. Mood change
5. hormonal imbalance
6. abdominal pain
7. breast tenderness

 

---

---

Progyluton Tablet Contraindication

---

---

• Hormone replacement therapy (HRT) should not be started in the presence of any of the conditions listed below. should any of the conditions appear during HRT use?the product should be stopped immediately.
• Pregnancy
• Lactation meaning breastfeeding
• Venous Thromboembolism (VTE)
• (CAD)Coronary Arterial Disease   angina, myocardial infarction
• Ovarian cancer this cancer much rare in breast cancer.
• chronic liver diseases like HCV or HBS  or liver cirrhosis
• ischemic stroke (CVA)cerebrovascular accident
•  Hypersensitivity mean patient reaction due to  some drugs
• Undiagnosed vaginal bleeding.
• pulmonary  embolism

Progyluton Tablet Dose 

         How to start progyluton tablet

• If the patient is still Menstruating .treatment Should Begin on the 5th day of the cycle ( 1st day of menstrual Bleeding=1st day of the cycle).
• patient with amenorrhea or very infrequent periods or who are postmenopausal may start at any time, provided pregnancy has been excluded (see section pregnancy and lactation ).
• Dose
• one tablet Is taken daily for the first 11 days, followed by one light brown tablet daily for 10 days. following the 21 days of tablet-taking, there will be a tablet-free interval of 7 days.
• Dose and administration
• each pack covers 21 days of treatment. a new pack progyluton should be started after the 7-day tablet-free interval on the same day of the week as the previous one.
• the tablet is to be swallowed whole with some liquid.
• the tablet should preferably be taken at the same time every day.

• Missed Dose tablet

• In case a tablet is forgotten, It should be taken as soon as possible. if more than 24 hours have elapsed, no extra tablet needs to be taken. if several tablets are forgotten, bleeding may occur. 
• bleeding usually occurs during the tablet-free interval of 7 days within a few days after the last tablet was taken.

• additional information on special populations of children and adolescents.  

• porgyluton is not indicated for use in children and adolescents.

• Geriatric Patients

• There are no data suggesting a need for dosage adjustment in elderly patients.in women aged 65 years or older see section special warnings and precautions for use.

---

---

Progyluton Tablet Oral Uses(Estradiol-Valerate–Norgestrel) 

---

---

پروگلوٹان کو ہم زنانہ تکالیف میں استعمال کرتے ہیں
جب زنانہ بیماری باقائدگی سےنہ آتی ہو یا بار بار آتی ہوتو ان سب
کی وجہ ہارمونل پرابلم ہوتی ہےہارمون کی کمی بیشی سے
یہ مسئلہ پیدا ہوتاہےاور اس میں دو قسم کے ہارمون پائے جاتے
ہیں ایسٹروجن اور دوسرا پروجسٹرون پائے جاتے ہیں اس کو
لیول میں کرتی ہیں اور زنانہ ہارمون کو لیول میں کرتی ہے

پروگلوٹان کو ہم مختلف زنانہ تکالیف میں ہم استعمال کرتے ہیں
ہارمونل ایمبیلنسمنٹ میں استعمال کراتے ہیں
سیکنڈری آیمینوریا میں استعمال کراتے ہٰٰٰٰیں
ماہواری کا بار بار آنااسکو عورتیں حاملہ ہونے کےلئے استعمال کر سکتی

ہیں اور اس سے انڈا کااخراج ہوتا ہےجس عورتیں کنسیو کرسکتی ہیں

PROGLUTON Oral Uses

Estadiol valerate

Norgestrel

NAME OF THE MEDICALE PRODUCT

Proglyuton

 

QUALITATIVE AND QUANTITATIVE

COMPOSITION

Each white sugar-coated tablet contains estradiol valerate 2.0mg

Each light brown sugar-coated tablet contains estradiol valerate 2.0 mg and norgestrel 0.5mg

 

Progyluton tablet oral Uses Dosage

• One white tablet is taken daily for the first 11 days, followed by one light brown tablet daily for 10 days.
• Following the 21 days of tablet-taking, there will be a tablet-free interval of 7 days.

Progyluton Oral Uses Administration

Each pack covers 21 days of treatment. A new pack of should be Progyluton started after the 7- day tablet-free interval on the same day of the week as the previous one.

The tablets are to be swallowed whole with some liquid.

The tablets should preferably be taken at the same time every day.

Missed tablets

In case a tablet is forgotten, it should be taken as soon as possible. If more than 24 hours have elapsed. No extra tablet deeds to be taken, if several tablets are forgotten, bleeding may occur. Bleeding usually occurs during the tablet-free interval of 7 days within a few days after the last tablet was taken.

Additional information on special populations

Children and adolescents

Progyluton is not indicated for use in children and adolescents.

Geriatric patients

There are no data suggesting a need for dosage adjustment in elderly patients. In women aged 65 years or older see section special warnings and precaution for use.

Patients with hepatic impairment

Progyluton has not been specifically studied in renal impaired patients. Available data do not suggest a need for dosage adjustment in this patients population.

Progyluton tablet Contraindications

Hormone replacement therapy (HRT) should not be started in the presence of any of the conditions listed below. Should any of the conditions appear during HRT use, the product should be stopped immediately?

• Pregnancy and lactation
• Undiagnosed vaginal bleeding
• Known or suspected cancer of the breast or malignancies, if sex steroid-influenced
• Presence or history of liver tumors ( benign or malignant)
• Severe hepatic disease
• Acute arterial thromboembolism (e.g myocardial infarction, stroke)
• Active deep venous thrombosis, thromboembolic disorders, or a documented history of these conditions
• A high risk of venous or arterial thrombosis
• Severe hypertriglyceridemia
• Known hypersensitivity to any of the components of progyluton

Progyluton tablet Special warnings and precautions for use

During HRT use, therapy should not be used in this situation

• Migrainous or frequent and unusually severe headaches that occur for the first time or other symptoms that are possible prodroma of cerebrovascular occlusion.
• Recurrence of cholestatic jaundice or cholestatic pruritus which occurred first during pregnancy or previous use of sex steroids.
• Symptoms of a thrombotic event or suspicion thereof.

Interaction with other medicinal products and other forms of interaction

Effects of other medicinal products on progyluton

 Interactions can occur with drugs that induce microsomal enzymes which can result in increased clearance of sex hormones and which may lead to changes in the uterine bleeding profile and/or reduction of the therapeutic effect.

Substances increasing the clearance of sex hormones ( diminished efficacy by enzyme- induction)

 Phenytoin, barbiturates, primidone, carbamazepine, rifampicin and possibly also oxcarbazepine, topiramate, felbamate. Griseofulvin and products containing St. john’s wort.

Enzyme induction can already be observed after a few days of treatment. Maximal enzyme induction is generally seen within a few weeks. After the cessation of drug therapy, enzyme induction may be sustained for about 4 weeks

Other forms of interaction

 Laboratory tests

 The use of sex steroids may influence the results of certain laboratory tests.

Pregnancy and lactation

HRT Medication not Used during pregnancy or lactation. If pregnancy occurs during medication with progyluton, treatment should be discontinued immediately.

Sex hormones excreted in human milk.

 

System organ class MedDRA V. 8.0	Common (≥/100,</10)	Uncommon (≥1/1000 <1/100)	Rare (≥1/10,000, <1/100)
Immune system disorders		Hypersensitivity Reaction
Metabolism and nutrition disorders	Weight increase Weight increase
Psychiatric disorders		Depressed mood	Anxiety, Libido decreased Libido increased
Nervous system	Headache	Dizziness	Migraine
Eye disorders		Visual disturbances	Contact lens intolerance
Cardiac disorders		Palpitations
Gastrointestinal disorders	Abdominal pain, Nausea	Dyspepsia	Bloating, vomiting
Skin and subcutaneous tissue disorders	Rashes, pruritus	Erythema nodosum, Urticaria	Hirsutism, Acne
Musculoskeletal and connective tissue disorders			Muscle cramps
Reproductive system and breast disorders	Uterine/vaginal Bleeding including Spotting (bleeding irregularities usually subside during Continued treatment	Breast  pain, Breast tenderness	Dysmenorrhea, Vaginal discharge, Premenstrual- like syndrome, Breast enlargement,
General disorders and administration site conditions		Edema	fatigue